Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 7282 | Other Identifier | NIHR |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| British Skin Foundation | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet B phototherapy by using validated objective and subjective scoring systems.
Children with moderate to severe atopic eczema prescribed a course of narrowband UVB phototherapy were scored (using validated scoring systems) objectively and subjectively before, during and after the course of treatment, as well as 3 and 6 months post treatment (to determine length of remission). Their scores were compared to a control group. The control group comprised children with moderate to severe atopic eczema who were offered UVB but were unable to undertake the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UVB | Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy |
| |
| Controls | Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Narrowband Ultraviolet B phototherapy | Radiation | Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Score at the end of treatment compared to the control group | Measurement of Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected of those treated with narrowband UVB as compared to a control group | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective scores at the end of treatment as compared to controls | Subjective scoring using Patient Outcome Eczema Measure (POEM), Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual analogue scale (VAS) for itch and sleep loss | 12 weeks |
| objective scores at 3 months post treatment compared to controls |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Children aged 3-16 years
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aileen EM Taylor, MBChB | Royal Victoria Infirmary | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Victoria Infirmary | Newcastle upon Tyne | NE1 4LP | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
Not provided
Not provided
Not provided
saliva
Objective Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected in the treated group at 3 months post treatment as compared to controls. |
| 3 months |
| Association of filaggrin status with outcome | To determine if response to phototherapy is determined by the presence of a homozygous or compound heterozygous filaggrin mutation. | 12 weeks |
| Subjective scores at 3 months post treatment compared to controls | Subjective scores (Patient Outcome Eczema Measure (POEM),Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual Analogue Scale (VAS) for itch and sleep loss) in the treated group at 3 months post treatment as compared to controls. | 3 months |
| Subjective scores at 6 months post treatment compared to controls | Subjective scores (Patient Outcome Eczema Measure (POEM),Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual Analogue Scale (VAS) for itch and sleep loss) in the treated group at 6 months post treatment as compared to controls. | 6 months |
| Objective scores at 6 months post treatment compared to controls | Objective Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected in the treated group at 6 months post treatment as compared to controls. | 6 months |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |